Shareholders’ Equity |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Equity [Abstract] | |
| Shareholders’ Equity | Shareholders’ Equity September 2026 Equity Offering On September 10, 2026, the Company entered into an underwriting agreement (the “September Underwriting Agreement”) with BofA Securities, Inc., Jefferies LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the “September Underwriters”). Pursuant to the terms and conditions of the September Underwriting Agreement, the Company agreed to sell 4,910,000 shares of its common stock, $0.01 par value per share, at a public offering price of $42.50 per share (the “Initial Offering”), plus an additional 736,500 shares pursuant to the September Underwriters’ option to purchase additional shares (the “Greenshoe Offering” and together with the Initial Offering, the “September 2026 Offering”). The Initial Offering closed on September 11, 2026 and the Greenshoe Offering closed on September 16, 2026 with an aggregate sale of 5,646,500 shares. The Company received net proceeds from the September 2026 Offering of $225,029, after deducting the underwriting discounts and commissions, and expenses in connection with the September 2026 Offering. Net proceeds from the September 2026 Offering were used to fund the BioCircuit Acquisition and related fees and expenses, with the remaining net proceeds to be used for general corporate purposes. See Note 16 - Subsequent Events for details regarding the BioCircuit Acquisition. January 2026 Equity Offering On January 21, 2026, the Company entered into an underwriting agreement (the “January Underwriting Agreement”) with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters (the “January Underwriters”). Pursuant to the terms and conditions of the January Underwriting Agreement, the Company agreed to sell 4,000,000 shares of its common stock, $0.01 par value per share, at a public offering price of $31.00 per share, plus an additional 600,000 shares pursuant to the January Underwriters’ option to purchase additional shares. The January 2026 Offering closed on January 23, 2026 with a sale of 4,600,000 shares. The Company received net proceeds from the January 2026 Offering of $133,252, after deducting the underwriting discounts and commissions, and expenses in connection with the January 2026 Offering. Net proceeds from the January 2026 Offering were used for the early payoff and termination of the Credit Facility for a final repayment amount of $69,707. The remaining net proceeds to be used for working capital, capital expenditures and other general corporate purposes. See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees for details regarding the termination of the Credit Facility.
|